Plain Language Summary of the manuscript: ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathy

Dong Nguyen, Quan; P. Ehlers, Justis; S. Boyer, David; Jin, Xidong; Giani, Andrea; S. Ehrlich, Michael

doi:10.60915/Boehringer-figshare.27720054.v2

Plain Language Summary of the manuscript: ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathy

journal contribution

posted on 2024-11-22, 08:00 authored by Quan Dong Nguyen, Justis P. Ehlers, David S. Boyer, Xidong Jin, Andrea Giani, Michael S. Ehrlich

The above is a plain language summary of a publication developed with the authors of the original content which is published in a peer-reviewed scientific journal.

Funding

This study was sponsored by Boehringer Ingelheim. Medical writing support provided by Open Health. Medical Writing support and open access APCs were funded by Boehringer Ingelheim.

History

Disclaimer

The PLS content is not peer-reviewed. Unless otherwise specified, the content on this website has undergone a medical, legal, and regulatory (MLR) review and medical scientific accuracy review by Boehringer Ingelheim. The publisher of the original manuscript was not involved in the preparation of this PLS and has neither reviewed nor approved its content.

Plain Language Summary of the manuscript: ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathy

Funding

This study was sponsored by Boehringer Ingelheim. Medical writing support provided by Open Health. Medical Writing support and open access APCs were funded by Boehringer Ingelheim.

History

Disclaimer

More information

Usage metrics

Categories

Keywords

Licence

Exports